- Home
- OSRHW vs ERNAW Comparison
OSRHW vs ERNAW Comparison
Compare OSRHW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OSRHW | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 21 | 6 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | OSRHW | ERNAW |
|---|---|---|
| Price | $0.06 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.7K | ★ 40.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.05 |
| 52 Week High | $0.08 | $0.11 |
Technical Indicators
Market Signals| Indicator | OSRHW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 56.67 |
| Support Level | $0.04 | $0.05 |
| Resistance Level | $0.07 | $0.11 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 15.67 | 66.72 |
Price Performance
Historical ComparisonAbout OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About ERNAW Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.